CVS Health Inc. CVS on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to ...

Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its ...

Amgen Inc (AMGN) reports robust sales growth with 14 blockbuster products, while navigating competitive pressures and strategic pivots.

When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of ...

(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - ...

At 05:55 ET (10:55 GMT), Dow Jones Futures traded 150 points, or 0.3%, higher, S&P 500 Futures gained 10 points, or 0.1%, and ...

Check out some of the stocks making the biggest moves in midday trading. Bitcoin-related plays — Stocks related to the ...

Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire.

Amgen (NasdaqGS:AMGN) ended its eczema drug partnership with Kyowa Kirin involving the experimental therapy rocatinlimab. The company also received an FDA request to withdraw Tavneos, a treatment for ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...

After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to ...